RexMedical- Option* Vena Cava Filter IDE Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00488865
Recruitment Status : Completed
First Posted : June 20, 2007
Results First Posted : August 5, 2010
Last Update Posted : August 10, 2010
Information provided by:
Rex Medical

Brief Summary:
This study is designed to evaluate the safety and efficacy of the RexMedical Option* Vena Cava Filter in the treatment of patients who are at increased risk for Pulmonary Embolism and require caval interruption.

Condition or disease Intervention/treatment Phase
Pulmonary Embolism Device: Intravascular Filter Device Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: RexMedical- Option* Vena Cava Filter IDE Study
Study Start Date : October 2006
Actual Primary Completion Date : December 2008
Actual Study Completion Date : June 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Intravascular Filter Device Device: Intravascular Filter Device
Vena cava filter which is implanted into the inferior vena cava of patients to prevent recurrent pulmonary embolism. The filter can be utilized as a permanent or retrievable device.

Primary Outcome Measures :
  1. Percentage of Participants With Clinical Success [ Time Frame: up to 180 days ]
    Placement Technical Success without subsequent pulmonary embolism, significant filter migration, symptomatic caval thrombosis or other complication requiring filter removal or invasive intervention to address condition.

  2. Percentage of Participants With Retrieval Clinical Success [ Time Frame: upto 175 days ]
    Intact filter retrieval via percutaneous techniques from the vasculature without associated injury or damage to the vena cava requiring intervention.

Secondary Outcome Measures :
  1. Placement Technical Success [ Time Frame: Immediately post placement procedure ]
    Successful deployment of the filter at the intended placement level such that the filter is judged suitable by the Investigator for mechanical protection against pulmonary embolism.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Patient is at least 18 years of age
  • Patient requires temporary or permanent caval interruption

Key Exclusion Criteria:

  • Patient has pre-existing filter implanted in her/her vasculature or has undergone filter retrieval within 60 days prior to study device implant
  • Patient is currently enrolled in another investigational device or drug trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00488865

United States, California
Peninsula Surgical Specialists Medical Group, Inc.
Burlingame, California, United States, 94010
United States, Delaware
Christiana Care Health System
Newark, Delaware, United States, 19713
United States, District of Columbia
George Washington University
Washington, District of Columbia, United States, 20037
United States, Florida
Miami Cardiac & Vascular Institute
Miami, Florida, United States, 33176
United States, Illinois
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611
United States, Indiana
Indiana University School of Medicine
Indianapolis, Indiana, United States, 46202
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
United States, New York
New York Presbyterian Hospital/Columbia
New York, New York, United States, 10032
United States, Oregon
Portland, Oregon, United States, 97201
United States, Texas
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390
Sponsors and Collaborators
Rex Medical

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Lindsay Carter, Rex Medical Identifier: NCT00488865     History of Changes
Other Study ID Numbers: REX-US-2006-001
First Posted: June 20, 2007    Key Record Dates
Results First Posted: August 5, 2010
Last Update Posted: August 10, 2010
Last Verified: August 2010

Keywords provided by Rex Medical:
increased risk for PE require caval interruption

Additional relevant MeSH terms:
Pulmonary Embolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases